Tag Archives: Auto-Injectors Market

Auto Injectors Market Offering High-growth Opportunities for Market Players

Auto-injectors are hypodermic syringes used to administer a single dose of a drug (typically any life saving drug). These are easy to use and are intended either for self-administration or by untrained personnel. The commercially available auto-injectors are majorly used for the management of anaphylaxis, multiple sclerosis and rheumatoid arthritis. High prevalence of anaphylaxis and food allergies is the major factor propelling the growth of the global auto-injectors market. According to the European Academy of Allergy and Clinical Immunology (EAACI), there has been a seven-fold increase in anaphylaxis related hospital admissions in Europe from 2003 to 2013. Similarly, the Australasian Society of Clinical Immunology and Allergy (ASCIA) stated that the number of anaphylaxis associated hospital admissions increased five times from 2004 to 2014 in New Zealand and Australia. Rising prevalence of anaphylaxis and food allergies is increasing the demand for epinephrine auto-injectors used for anaphylaxis management. Moreover, Healthline Networks, a provider of health information and technology solutions for advertisers, publishers, employers, and health plans and healthcare providers, stated that 2.5 million people were suffering from multiple sclerosis in 2013 worldwide. High prevalence of multiple sclerosis and rheumatoid arthritis is increasing the demand for novel treatment options among the patients, which in turn drives demand for auto-injectors globally.

Read Full Report: http://www.transparencymarketresearch.com/global-auto-injectors-market.html

Based on product types, the global auto-injectors market has been categorized into prefilled auto-injectors and fillable auto-injectors. Prefilled auto-injectors dominate the auto-injectors market due to their offered ease-of-use and rising patient awareness. Based on Therapeutic Applications, the global auto-injectors market has been segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The anaphylaxis segment was the leading and fastest growing market majorly due to high prevalence of the disease, rising awareness about epinephrine auto-injectors and advantages of its use for anaphylaxis management during emergency situations. Based on the manufacturing design, the auto-injectors market has been segmented into standardized auto-injectors and customized auto-injectors. Standardized auto-injectors dominated the market in 2013, as these are the oldest and most preferred auto-injectors with an established record of effective results. However, customized auto-injectors is estimated to be the fastest growing segment, as these offer customization of the dosage of the drug according to age, sex and need of the patient.

Geographically, the global auto-injectors market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the global auto-injectors market in 2013 due to high prevalence of anaphylaxis, favorable government reimbursement policies and economic stability to purchase expensive auto-injectors in the region. On the other hand, Asia Pacific is estimated to be the most promising market for auto-injectors during the forecast period due to rising prevalence of anaphylaxis and multiple sclerosis in New Zealand and Australia coupled with the government reimbursement options in New Zealand, and rising awareness about novel treatment methods available in the market.

Get a Sample for this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4199

The auto-injectors market is consolidated and dominated by a few market players. Mylan, Inc. and Sanofi led the standardized auto-injectors segment due to higher demand for EpiPen and Auvi-Q auto-injectors, respectively. However, the SHL Group dominated the customized auto-injectors segment, with a wide product offering of prefilled customized auto-injectors. The other major companies operating in the auto-injectors market include Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Novartis International AG, Pfizer, Inc., Unilife Corporation and Ypsomed Holdings AG. The auto-injectors market is innovation driven, therefore market players are constantly engaged in research and development activities in order to develop new and effective auto-injectors against various diseases.

 

Leading Players in Auto Injectors Market

syringe-145002_640

Auto-injectors are hypodermic syringes used to administer a single dose of a drug (typically any life saving drug). These are easy to use and are intended either for self-administration or by untrained personnel. The commercially available auto-injectors are majorly used for the management of anaphylaxis, multiple sclerosis and rheumatoid arthritis. High prevalence of anaphylaxis and food allergies is the major factor propelling the growth of the global auto-injectors market. According to the European Academy of Allergy and Clinical Immunology (EAACI), there has been a seven-fold increase in anaphylaxis related hospital admissions in Europe from 2003 to 2013. Similarly, the Australasian Society of Clinical Immunology and Allergy (ASCIA) stated that the number of anaphylaxis associated hospital admissions increased five times from 2004 to 2014 in New Zealand and Australia. Rising prevalence of anaphylaxis and food allergies is increasing the demand for epinephrine auto-injectors used for anaphylaxis management. Moreover, Healthline Networks, a provider of health information and technology solutions for advertisers, publishers, employers, and health plans and healthcare providers, stated that 2.5 million people were suffering from multiple sclerosis in 2013 worldwide. High prevalence of multiple sclerosis and rheumatoid arthritis is increasing the demand for novel treatment options among the patients, which in turn drives demand for auto-injectors globally.

Based on product types, the global auto-injectors market has been categorized into prefilled auto-injectors and fillable auto-injectors. Prefilled auto-injectors dominate the auto-injectors market due to their offered ease-of-use and rising patient awareness. Based on Therapeutic Applications, the global auto-injectors market has been segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis and others. The anaphylaxis segment was the leading and fastest growing market majorly due to high prevalence of the disease, rising awareness about epinephrine auto-injectors and advantages of its use for anaphylaxis management during emergency situations. Based on the manufacturing design, the auto-injectors market has been segmented into standardized auto-injectors and customized auto-injectors. Standardized auto-injectors dominated the market in 2013, as these are the oldest and most preferred auto-injectors with an established record of effective results. However, customized auto-injectors is estimated to be the fastest growing segment, as these offer customization of the dosage of the drug according to age, sex and need of the patient.

Get a Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4199

Geographically, the global auto-injectors market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America dominated the global auto-injectors market in 2013 due to high prevalence of anaphylaxis, favorable government reimbursement policies and economic stability to purchase expensive auto-injectors in the region. On the other hand, Asia Pacific is estimated to be the most promising market for auto-injectors during the forecast period due to rising prevalence of anaphylaxis and multiple sclerosis in New Zealand and Australia coupled with the government reimbursement options in New Zealand, and rising awareness about novel treatment methods available in the market.

The auto-injectors market is consolidated and dominated by a few market players. Mylan, Inc. and Sanofi led the standardized auto-injectors segment due to higher demand for EpiPen and Auvi-Q auto-injectors, respectively. However, the SHL Group dominated the customized auto-injectors segment, with a wide product offering of prefilled customized auto-injectors. The other major companies operating in the auto-injectors market include Antares Pharma, Inc., Becton, Dickinson and Company, Biogen Idec, Inc., Novartis International AG, Pfizer, Inc., Unilife Corporation and Ypsomed Holdings AG. The auto-injectors market is innovation driven, therefore market players are constantly engaged in research and development activities in order to develop new and effective auto-injectors against various diseases.

Global Auto Injectors Market to Exceed US$2.5 bn by 2020 Led by Demand for Pre-filled Auto Injectors

Driven by the rising incidence of conditions such as anaphylaxis in developed countries and the creation of a favorable reimbursement scenario by governments across the world, the global auto injectors market is poised to log a CAGR of 18.6% from 2014 to 2020. These findings are published in Transparency Market Research’s study, titled ‘Auto-Injectors Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020’.

Browse the full Auto-injectors Market (Product Types: Prefilled and Fillable Auto-injectors; Therapeutic Applications: Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis and Others; Manufacturing Design: Standardized and Customized Auto-injectors) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020 report at http://www.transparencymarketresearch.com/global-auto-injectors-market.html

The study states that the global auto-injectors market will rise from its 2013 valuation of US$665.0 mn to rise to US$2.5 bn by 2020, with enormous opportunities existing in RoW markets and emerging economies. An alarming increase in the prevalence of rheumatoid arthritis and various food allergies will further create opportunities for the growth of the auto injectors market globally. TMR analysts identify a major roadblock standing in the way of companies trying to occupy a larger revenue share in the auto-injectors market: The high prices of auto-injectors. The price factor assumes greater importance when it comes to patients in emerging economies, where, incidentally, the most lucrative growth opportunities lie.

Even so, the demand for auto injectors will continue to rise consistently as patients opt to choose these products for their ease of use, even during self-administration. The report segments the global auto injectors market on the basis of product type, manufacturing design, therapeutic application, and geography. On the basis of product type, the market is segmented into prefilled or disposable auto injectors and fillable or reusable auto injectors. Given their unmatched ease of use, pre-filled auto injectors made up the largest segment in the auto injectors market by product type.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4199

Likewise, using manufacturing design as a criterion, the global auto-injectors market has been segmented into customized and standardized auto injectors. Although the standardized injectors segment was the larger one in 2013, the growth of the customized auto-injectors segment will be the fastest through the report’s forecast period.Moving further, the report segments the auto-injectors market by therapeutic application into anaphylaxis, rheumatoid arthritis, multiple sclerosis, and others. The high prevalence of anaphylaxis has created a massive demand for auto injectors for administrating drugs to people suffering from this condition. This factor has made the anaphylaxis the largest application segment in the auto injectors market.

From the geographical standpoint, the market for auto injectors is segmented into North America, Asia Pacific, Europe, and Rest of the World (RoW). Claiming a 70% stake in the global auto-injectors market, North America was seen to be the largest regional market in 2013. While the dominant position of North America will not see a drastic change, the Asia Pacific market will report the fastest rate of growth. The key recommendations of TMR’s analysts, discussed in detail in the report, include: Channeling investments into China and India, spearheading innovation in auto injectors, and improving consumer awareness through marketing campaigns.

Companies profiled in detail in the auto-injectors market report include: Pfizer, Inc., Becton, Dickinson & Co., Mylan, Inc., Antares Pharma Inc., Novartis International AG, Unilife Corp., Ypsomed Holding AG, Biogen Idec, and Scandinavian Health Ltd.

Auto-Injectors Market to be Driven by Increasing Consumer Awareness and Favorable Government Initiatives

Auto-injectors are medical devices used to deliver a one-shot dose of medication. They are often used to ward off the effects of life-threatening or other extremely uncomfortable and painful conditions urgently. Conditions for which auto-injectors are beneficial include anaphylaxis, rheumatoid arthritis, and multiple sclerosis. Due to their urgent, vital nature, they are designed to be ‘auto-injected’, i.e. used by the patient him/herself.

The global auto-injectors market was worth US$665 million in 2013 and, aided by increasingly favorable reimbursement policies, government aid, and efforts by auto-injector manufacturers to make the masses aware of their crucial product, is expected to rise to more than US$2,500 million, or US$2.5 billion, by 2020. This represents a stupendous CAGR of 18.6%.

Auto-injectors help counter conditions that, until but a few years ago, required the attention of a trained healthcare professional. This is a major leap in healthcare infrastructure development, in line with an overall trend of increasing preference for in-home medication and treatment. Auto-injectors are a vital part of a set of factors such as advanced telecommunication technologies, wider spread of healthcare infrastructure, and the availability of other advanced medical devices, which are enabling healthcare professionals to remotely monitor patients. This makes the process more convenient for both parties, eliminating the erstwhile need of patients to actually visit the practitioner.

Read Full Press Release : http://www.transparencymarketresearch.com/pressrelease/global-auto-injectors-market.htm

Rising Anaphylaxis in Oceania to Drive Asia Pacific Auto-Injectors Market

According to the geographical segmentation of the global auto-injectors market, North America accounted for more than 70% of the global market in 2013. North America’s domination of the global auto-injectors market can be attributed to the widespread incidence of food allergies, leading to anaphylaxis, and rheumatoid arthritis; and highly advanced medical innovation leading to easier availability of auto-injectors.

Even though consumers in many Asia Pacific countries still find regular use of auto-injectors beyond their wallet, increasing development in Southeast Asia and Oceania is expected to make Asia Pacific the dominant geographical segment in the global auto-injectors market. Cases of anaphylaxis are on the rise particularly in Australia and New Zealand, two of the most developed countries in Asia Pacific. This is expected to provide a major boost to the Asia Pacific market for auto-injectors. Increasing spending power in developing economies such as China, India, South Korea, and Japan will also bring auto-injectors closer to the masses.

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4199

Standard Prefilled Auto-Injectors Dominate Global Auto-Injectors Market

According to product type and manufacturing process, the global auto-injectors market into prefilled and fillable auto-injectors, and standard and customized auto-injectors, respectively.

The higher ease of use offered by prefilled auto-injectors has resulted in a dominant market share for the segment. Prefilled auto-injectors also offer immediate usage, whereas the valuable moments spent filling up an auto-injector could be extremely costly in matters of life and death.

Standard auto-injectors, being older and more established, are more popular around the world due to their robust simplicity. However, increasing medical innovation has led to the conception of auto-injectors whose dosage is customized minutely according to the severity of the patient’s condition, his/her allergies, age, etc. Due to the higher sophistication, customized auto-injectors cost more and are not expected to threaten the dominance of standard auto-injectors any time soon. However, their increased precision will help increase demand for them, which will lower the prices, bringing it closer to the masses.

Mylan Inc., Sanofi, SHL Group Dominate Concentrated Auto-Injectors Market

The auto-injectors market is driven by innovation, with technological advancement virtually guarantedd to pay off in today’s constantly evolving healthcare scenario. The concentrated market is led by companies such as Mylan Inc., Scandinavian Heath Limited (SHL) Group, Ypsomed Holding AG, Sanofi, Pfizer Inc, Novartis International AG, etc. Promotional efforts by major market players such as Mylan Inc. and Ypsomed Holding AG have helped the expansion of the market massively and continue to boost the market in emerging Asia Pacific economies.

Browse Full Global Auto-Injectors Market Report With Complete TOC @ http://www.transparencymarketresearch.com/global-auto-injectors-market.html

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Mr. Sudip S

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/